Cost and Coverage of Originator and Biosimilar Ustekinumab Products in Medicare Part D

Дата публикации: 17-08-2026 00:00:00

This cross-sectional study investigates the cost and coverage of ustekinumab originator Stelara and biosimilar products in 2026 for Medicare Part D.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	A Clinically Relevant Threshold of Impaired Contrast Sensitivity Among Older US Adults	0	8.8	01-07-2026
2	Prostate-Specific Membrane Antigen Imaging and Initial Treatment for Prostate Cancer	0	10.24	01-07-2026
3	Federal Housing Assistance and Survival in Older Adults With NSCLC	0	8.64	30-07-2026
4	Metformin Use and Age-Related Macular Degeneration in Patients With Diabetes	0	9.02	01-07-2026
5	Meta-analysis of the Efficacy and Safety of Ustekinumab in the Treatment of Pediatric Inflammatory Bowel Disease	0	15.31	07-08-2026
6	He Kept a Stand-Alone Drug Plan With Original Medicare. It Costs Four Times as Much as Advantage Drug Coverage and Its Federal Cushion Ends After 2026.	0	7.61	13-08-2026
7	Efficacy and Safety of Azathioprine in Ulcerative Colitis with 5-aminosalicylic acid Intolerance: A Single-Center Retrospective Cohort Study	0	18.7	10-08-2026
8	Opinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs	0	13.11	11-08-2026
9	STAT+: Medicare takes another swing at 340B cuts to hospitals	0	5	02-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 6.92. Источник: jamanetwork.com.